

12<sup>a</sup>  
ACTUALIZACIÓN  
en el TRATAMIENTO  
**LEUCEMIA**  
AGUDA 2023



del 5 al 7  
**OCT**  
2023

**Dr Priyanka Mehta**

*Consultant Haematologist, University Hospital of  
Bristol and Weston NHS Foundation Trust, Bristol, UK*

After completing a post-graduate degree in Internal Medicine from the University of Mumbai, India, Dr Priyanka Mehta trained in haematology, initially at the University Hospitals of Wales, Cardiff, and later in the West Midlands, UK. Dr Mehta has been a consultant haematologist at the University Hospitals Bristol and Weston NHS Trust since 2007.

Dr Mehta's main clinical and research interest is the field of myeloid malignancies. She is a member of the UK NCRI AML working group and the European Group for Blood and Marrow Transplantation Chronic Leukaemia Working Party. Dr Mehta's academic interests are the mechanisms of resistance and chemosensitivity of myeloid blasts in AML, the role of comprehensive geriatric assessments in predicting outcomes in older patients treated for myeloid malignancies and implementation of clinical and laboratory evidence/ best practice in the real world. She is leading the development of the first UK AML Registry.